ADC Therapeutics Earnings Call: Trials, Cash And Risks

ADC Therapeutics Ltd ((ADCT)) has held its Q4 earnings call. Read on for the main highlights of the call.

ADC Therapeutics’ latest earnings call struck a cautiously optimistic tone, balancing solid clinical momentum and tighter cost control against flat commercial demand and ongoing losses. Management highlighted strong response data from key trials, reduced operating expenses, and an extended cash runway into 2028, but acknowledged that future value hinges on pivotal readouts and navigating intensifying competition.

Revenue Growth Driven by Q4 Upswing

ZYNLONTA delivered net product revenues of $22.3 million in Q4 2025, up about 36% from $16.4 million a year earlier, buoyed by customer ordering patterns and new account activation. Full-year 2025 revenue grew more modestly, rising 6.2% to $73.6 million versus $69.3 million in 2024, underscoring that the year’s strength was concentrated late and remains sensitive to ordering variability.

Compelling Clinical Signals from LOTIS-7 and LOTIS-5

Updated Phase Ib LOTIS-7 data showed a striking 90% best overall response rate and 78% complete response rate in 49 efficacy-evaluable patients with at least six months of follow-up. The LOTIS-5 safety lead-in also impressed, with an 80% overall response rate and 50% complete response rate, reinforcing the potential for competitive second-line efficacy if larger, randomized data confirm these signals.

Stacked Clinical Catalysts Over the Next Two Years

Management laid out a clear roadmap of near-term milestones, led by LOTIS-5 top-line progression-free survival data expected in Q2 2026, with full results by year-end and potential regulatory filings in 2027. LOTIS-7 is slated to deliver full data and publications by the end of 2026, while investigator-initiated indolent lymphoma data are anticipated between late 2026 and mid-2027, providing multiple shots on goal.

Deep Cost Cuts Sharpen Operating Discipline

ADC Therapeutics has moved aggressively to resize its cost base, citing a roughly 50% reduction in operating cost structure following strategic reprioritization. Adjusted operating expenses fell to $39.4 million in Q4 2025 and $181.3 million for the full year, declines of about 15% and 6% respectively versus prior periods, largely driven by lower R&D spending and broad expense controls.

Narrowing GAAP Losses Show Financial Progress

GAAP net loss narrowed sharply to $6.4 million in Q4 2025, or $0.04 per share, from $30.7 million in the prior-year quarter, reflecting both non-cash royalty adjustments and reduced R&D. For 2025, net loss improved to $142.6 million from $157.8 million in 2024, indicating progress on the path toward financial sustainability even as the business remains unprofitable.

Balance Sheet Bolstered and Runway Extended

The company ended 2025 with $261.3 million in cash and equivalents, up from $250.9 million a year earlier, aided by a $100 million PIPE in June and a $60 million PIPE in October. Management now expects its cash runway to extend at least into 2028, giving the company time to execute its clinical programs and prepare for potential label expansions without immediate financing pressure.

Building a Commercial Beachhead in DLBCL

On the commercial front, ADC Therapeutics has established roughly 10% share in third-line and later diffuse large B-cell lymphoma as a monotherapy. Its field force now covers about 90% of the DLBCL opportunity, and management plans targeted commercial and medical science liaison investments ahead of a potential second-line launch should the LOTIS programs succeed.

Flat Underlying Volume Caps Near-Term Upside

Despite the strong Q4 revenue print, management emphasized that underlying ZYNLONTA volume was broadly flat year over year, with growth driven more by order timing than true demand expansion. They cautioned that sales are likely to track roughly in line with recent history until new approvals or compendia inclusions open up larger second-line and combination treatment markets.

Persistent Losses and High Operating Spend

While trimmed, the company’s expense base remains heavy, with 2025 GAAP operating expenses totaling $202.9 million and Q4 GAAP operating expense at $41.0 million, including restructuring and impairment charges tied to the strategic plan. The full-year GAAP net loss of $142.6 million highlights that the business still relies heavily on external capital ahead of any step-change in revenue.

Value Tied to Pivotal Data and Regulators

Management was clear that long-term value hinges on successful LOTIS-5 and LOTIS-7 outcomes and subsequent regulatory or compendia decisions that would expand ZYNLONTA’s use into earlier lines of therapy. Internal peak U.S. revenue scenarios in the mid-hundreds of millions to near $1 billion largely assume favorable readouts and approvals, underscoring the scientific and execution risk if trials underperform.

Rising Competitive Bar from Advanced Therapies

The evolving lymphoma landscape adds pressure, as bispecific antibodies and other complex options like CAR-T are gaining traction with strong complete response profiles. ZYNLONTA’s current monotherapy complete response rate trails some combination regimens, so its combination strategies must demonstrate clearly superior response rates and convenience to win share in a crowded field.

End-Point Complexity and Survival Uncertainty

LOTIS-5’s overall survival outcomes may be difficult to interpret given patient crossover and the growing use of subsequent therapies such as CAR-T and bispecifics. Management stressed that progression-free survival is the primary endpoint and key value driver, but conceded that any ambiguity around overall survival could limit differentiation on long-term outcomes versus rival regimens.

Royalty and Debt Structures Still Weigh

Although an amended agreement with HealthCare Royalty has given ADC Therapeutics more strategic flexibility, ongoing royalty and term loan obligations remain embedded in the model. These deferred royalty and financing commitments factor into capital allocation decisions and will continue to siphon a portion of future cash flows even if revenues ramp as planned.

Guidance Points to Catalyst-Rich 2026–2027

Looking ahead, the company reaffirmed that LOTIS-5 top-line progression-free survival data should arrive in Q2 2026, with full results by year-end and a potential supplemental filing and confirmatory approval timeline beginning in 2027. LOTIS-7 full data and indolent lymphoma publications are also slated through late 2026 to mid-2027, while management forecasts continued expense discipline, an R&D run-down over 2026–2027, and a sizable U.S. market opportunity that could support $600 million to $1 billion in peak revenue if key trials succeed.

ADC Therapeutics’ earnings call painted the picture of a company at an inflection point, backed by encouraging clinical data and a fortified balance sheet but still waiting for commercial proof at scale. For investors, the story now hinges on whether upcoming LOTIS readouts can convert scientific promise into sustained revenue growth before competition and obligations erode the opportunity.